Abstract
Biologic medicinal products developed via rDNA technology as recombinant protein-based medicines that have been in clinical use since the early 1980s as original biopharmaceuticals have greatly contributed to the therapy of severe metabolic and degenerative diseases. The recent expiration of the data protection or patents for most of them created opportunities for the development of copy versions of original biopharmaceuticals with similar biologic activity (termed biosimilars). Production of these new products is expected to meet worldwide demand, promote market competition, maintain the incentives for innovation, and sustain the healthcare systems. The licencing of these products, however, relies on the experience gained with the original biopharmaceuticals. Critical issues related to this class of medicinal products include their terminology (to avoid confusion with generics and non-innovator copy versions that have not been tested according to the biosimilar guidelines), manufacturing, and regulation. The European Union (EU) has been the first to establish a regulatory framework for marketing authorization application (MAA) and has named these products biosimilars, a term also recently adopted by the US FDA. Unlike the conventional, more common small molecular weight human medicines and chemical generics, protein-based medicines exhibit higher molecular weight, complexity in structure and function that can be affected by changes in the manufacturing process. Therefore, biosimilars represent a relatively heterogeneous class of medicinal products that make their regulation quite challenging. According to the current understanding in the EU, a biosimilar is a copy version of an already authorized biopharmaceutical (or reference product) with similar biologic activity, physicochemical characteristics, efficacy, and safety, based on a full comparability exercise at quality, preclinical and clinical level to ensure similar efficacy and safety. Guidance has been provided through several Committee for Medicinal Products for Human Use (CHMP) guidelines as well as individual scientific advice requested from the European Medicines Agency (EMA) by various companies for the development and regulation of biosimilars. This review is mainly focused on the current status of regulation of biosimilars in the EU as well as on future challenges lying ahead for the improvement of the requirements needed for the marketing authorization of biosimilars. Emphasis is given on the quality requirements concerning these medicinal products (biologics).
Similar content being viewed by others
References
Crommelin DJA, Sindelar RD, Meinbohm B. Pharmaceutical biotechnology: fundamentals and applications. 3rd ed. New York: Informa HealthCare; 2008.
Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov. 2008;7:21–9.
Carey K. Biosimilars encircle Rituxan, US debates innovator exclusivity. Nat Biotechnol. 2011;29:177–8.
Moran N. Biotech innovators jump on biosimilar bandwagon. Nat Biotechnol. 2012;30:297–9.
Ledford H. The same but different. Nature. 2007;449:274–6.
Lanthier M, Behram R, Nardinelli C. Economic issues with follow-on protein products. Nat Rev Drug Discov. 2008;7:733–7.
Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on products for human use. Official Journal of The European Communities L 159/46-94. http://ec.europa.eu/health/files/eudralex/vol-1/dir_2003_63/dir_2003_63_en.pdf [Accessed 2013 Feb 28].
Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC for medicinal products of Human use Official Journal of the European Community L 47:34–57 http://ec.europa.eu/health/files/eudralex/vol-1/dir_2004_27/dir_2004_27_en.pdf [Accessed 2013 Feb 28].
European Medicines Agency. Guideline on similar biological medicinal products (CHMP/437/04) http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf [Accessed 2013 Feb 28].
Tsiftsoglou AS. Biosimilars: the impact of their heterogeneity on regulatory approval. Nat Rev Drug Discov. 2007;6:1.
Weise M, Bielsky MC, DeSmet K, et al. Biosimilars: why terminology matters. Nat Biotechnol. 2011;29:690–3.
European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: Quality issues (EMEA/CHMP/BWP/49348/2005).
European Medicine Agency. Guidelines on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (EMEA/CHMP/BWPP/42832/2005).
European Medicine Agency. Guideline on comparability of biotechnology-derived medicinal products after a change in the manufacturing process-nonclinical and clinical issues (EMEA/CHMP/BMWP/101695/2006).
Schellekens H, Moors E. Clinical comparability and European biosimilar regulation. Nat Biotechnol. 2010;28:28–31.
Schneider CK, Borg JJ, Ehmann F, et al. In support of the European Union biosimilar framework. Nat Biotechnol. 2012;30(8):745–8.
European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies—non-clinical and clinical issues EMA/CHMP/BMWP/403543/2010.
FDA USA. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. February 2012.
Ruiz S, Calvo G. Similar biological medicinal products: lessons learned and challenges ahead. J Generic Med. 2011;6:4–13.
Covic A, Cannata-Andia J, Cancarini G, et al. Biosimilars and biopharmaceuticals: what the nephrologists need to know. A position paper by the ERA-EDTA Council. Nephrol Dial Transplant. 2008;23(12):3731–7.
McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. 2012;91(3):405–17.
Schück S, Texier N. Biosimilars: the French policy. Int J Risk Safe Med. 2009;21:41–5.
Another nail in the biosimilar coffin? [editorial]. Nat Biotechnol. 2012;30(3):198.
European Generic Medicines Association (EGA). Biosimilars handbook. 2nd ed. Thousand Oaks: Sage Publications Ltd; 2011.
European Medicines Agency. European public assessment reports: Valtropin [online]. http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&murl=menus%2Fmedicines%2Fmedicines.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars&genericsKeywordSearch=Submit [Accessed 2013 Feb 28].
Disclaimer
The views expressed in this article are the personal views of the author(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the European Medicines Agency or any of its committees or working parties.
Conflict of interest
The authors declare that they have no competing interests or other interests that must be perceived to influence the results and/or discussion reported in this review article.
Author information
Authors and Affiliations
Corresponding author
Additional information
A. S. Tsiftsoglou nominated as the representative of Greek National Medicine Agency to BWP/EMA.
Rights and permissions
About this article
Cite this article
Tsiftsoglou, A.S., Ruiz, S. & Schneider, C.K. Development and Regulation of Biosimilars: Current Status and Future Challenges. BioDrugs 27, 203–211 (2013). https://doi.org/10.1007/s40259-013-0020-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40259-013-0020-y